Description

6,11-Dihydro-11-(4-Piperidinylidene)-5H-Imidazo[2,1-B][3]Benzazepine (E)-2-Butenedioate (1:2) is a high-purity, non-racemic pharmaceutical intermediate and research chemical of significant commercial interest. This compound matters for its role as a key chiral building block in the synthesis of complex active pharmaceutical ingredients (APIs), where stereochemical purity is critical for efficacy and safety. Pharmaceutical R&D laboratories, process chemists, and fine chemical manufacturers need this material for developing and scaling up novel therapeutic agents, particularly in central nervous system (CNS) and other specialized drug discovery pipelines.

Application

• Pharmaceutical Intermediate: A critical chiral precursor in the multi-step synthesis of proprietary drug candidates and advanced APIs.
• Drug Discovery & Development: Used in medicinal chemistry for structure-activity relationship (SAR) studies and lead optimization in research settings.
• Process Chemistry & Scale-Up: Serves as a defined starting material or intermediate for process development, route scouting, and cGMP manufacturing campaigns.
• Reference Standard: Employed as an analytical standard for method development, validation, and quality control in pharmaceutical analysis.
• Biochemical Research: Utilized in pharmacological studies to investigate specific receptor interactions and biological pathways.
• Asymmetric Synthesis: Leveraged for constructing complex molecular architectures requiring high enantiomeric purity.

Basic Information

Product Name	6,11-Dihydro-11-(4-Piperidinylidene)-5H-Imidazo[2,1-B][3]Benzazepine (E)-2-Butenedioate (1:2)
CAS No.	174257-90-0
Molecular Formula	C21H21N3O8 (for the salt form, 1:2 fumarate)
Molecular Weight	443.41 g/mol
Synonyms	6,11-Dihydro-11-(4-piperidinylidene)-5H-imidazo[2,1-b][3]benzazepine fumarate (2:1); (E)-Butenedioic acid compound with 6,11-dihydro-11-(4-piperidinylidene)-5H-imidazo[2,1-b][3]benzazepine (2:1); Fumarate salt of Imidazobenzazepine derivative; UNII-8VK2578F0F; 174257-90-0; (E)-2-Butenedioic acid - 6,11-dihydro-11-(4-piperidinylidene)-5H-imidazo[2,1-b][3]benzazepine (2:1)
EINECS	Contact for details

Quality Control

Our 6,11-Dihydro-11-(4-Piperidinylidene)-5H-Imidazo[2,1-B][3]Benzazepine (E)-2-Butenedioate (1:2) is produced under strict quality management systems. Each batch undergoes rigorous analytical testing, including chiral purity assessment, to ensure compliance with stringent specifications for pharmaceutical intermediates. Certificates of Analysis (COA) detailing identity, purity, impurity profile, and residual solvents are provided and can be tailored to meet specific client or regulatory requirements (e.g., ICH guidelines).

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at a controlled room temperature (15-25°C). This material is hygroscopic (moisture-sensitive) and light-sensitive; therefore, containers must be kept tightly sealed in a dry environment and opened under controlled conditions to minimize exposure to atmospheric moisture and light.

Specification

Item	Specification
Appearance	White to off-white crystalline powder
Identification (IR)	Conforms to reference spectrum
Identification (HPLC)	Retention time corresponds to reference standard
Assay (HPLC)	≥ 98.0% (anhydrous basis)
Enantiomeric Purity (Chiral HPLC)	≥ 99.0% e.e.
Water Content (KF)	≤ 1.0% w/w
Residual Solvents (GC)	Meets ICH Q3C guidelines
Heavy Metals	≤ 20 ppm

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.